I agree. There are plenty of mice crawling around with enhanced memory. TC-5619 had been looked at in AD in a prior small clinical study. The results in Schizophrenia have sealed the compounds fate. The private company you referenced was Envivo and I feel the results are worth noting. ABBV and BMY are both working on compounds targeting A7.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.